A NEW, BREAKTHROUGH PRODUCT FOR FINANCIAL PLANNERS - USING STATE OF THE ART ACTUARIAL TECHNIQUES TO ANSWER THE NUMBER ONE QUESTION ON CLIENT'S (NEARING OR AT RETIREMENT) MINDS - DO I HAVE ENOUGH MONEY TO LAST THE REST OF MY LIFE?
A NEW, BREAKTHROUGH PRODUCT FOR FINANCIAL PLANNERS - USING STATE OF THE ART ACTUARIAL TECHNIQUES TO ANSWER THE NUMBER ONE QUESTION ON CLIENT'S (NEARING OR AT RETIREMENT) MINDS - DO I HAVE ENOUGH MONEY TO LAST THE REST OF MY LIFE?
This comprehensive review of trust owned life insurance will provide carrier, product and marketplace review as well as ongoing policy management. Trustees using our process may better manage this unique financial asset.
The Bogdahn Group Report to Orange County Commissioners laying out a "fiducia...Herb Whitehouse
Acceptance of this recommendation by Orange County Commissioners resulted in approximately a $1 million savings per year for Orange County employees.
I provided this document to Orange County Commissioners in 2008; therefore, the document is public information despite any license that the Slideshare form may indicate.
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Ashok-Leyland-Ltd-31 for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/JK-Lakshmi-Cement-Ltd-535
for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Federal-Bank-Ltd-3709 for more
This comprehensive review of trust owned life insurance will provide carrier, product and marketplace review as well as ongoing policy management. Trustees using our process may better manage this unique financial asset.
The Bogdahn Group Report to Orange County Commissioners laying out a "fiducia...Herb Whitehouse
Acceptance of this recommendation by Orange County Commissioners resulted in approximately a $1 million savings per year for Orange County employees.
I provided this document to Orange County Commissioners in 2008; therefore, the document is public information despite any license that the Slideshare form may indicate.
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Ashok-Leyland-Ltd-31 for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/JK-Lakshmi-Cement-Ltd-535
for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Federal-Bank-Ltd-3709 for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/I-G-Petrochemicals-Ltd-2202 for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Godrej-Agrovet-Ltd-16166 for more
LBS - Asset Allocation Model - July 2017 UpdateMark MacIsaac
We remain comfortable with our decision to adopt a neutral stance on equity vs. fixed income at the end of January as warning signals continued to appear in June
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Godrej-Agrovet-Ltd-16166 for more
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/SBI-Life-Insurance-Company-Ltd-22045 for more
Daily Derivatives Report:04 December 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
SBI Corporate Bond Fund: An Income Mutual Fund Scheme - Aug 16SBI Mutual Fund
SBI Corporate Bond Fund with moderate risk invests predominantly in corporate debt securities and aims to generate regular income over medium term. Mutual Fund investors can invest in this mutual fund via SIP or lump sum. Know more about this debt fund on SBI Mutual Fund website page https://www.sbimf.com/Products/DebtSchemes/SBI_Corporate_Bond_Fund.aspx
A thorough analysis of company , industry and economy goes behind our stock ideas for you. With these picks, you may earn superior returns over a medium to long term period. Visit https://simplehai.axisdirect.in/share-stock-prices/nse/Bajaj-Corp-Ltd-38716 for more
Daily Derivatives Report:24 December 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
Daily Derivatives Report:05 December 2019Axis Direct
Axis Direct presents daily derivatives report presenting recommendations based on technical analysis. For trading in derivatives visit https://simplehai.axisdirect.in/offerings/products/derivatives
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Call 8867766396 Satta Matka Dpboss Matka Guessing Satta batta Matka 420 Satta...
Cbli 2011 05 25 barda
1. LOS ANGELES | SAN FRANCISCO | NEW YORK | BOSTON | SEATTLE | MINNEAPOLIS | DALLAS
May 25, 2011
Gregory R. Wade, Ph.D. (415) 274-6863 David M. Nierengarten, Ph.D. (415) 274-6862 Christopher N. Marai, Ph.D. (415) 274-6861
Cleveland BioLabs, Inc. (CBLI - OUTPERFORM): BARDA Contract Progress Update
Price: $5.52 12-Month Price Target: $10
• We continue to anticipate that CBLI will receive a $50+ million government award for CBLB502 development
(BAA-BARDA-09-34) now in the July/August timeframe. It appears to us that the contract award announcement has
been delayed; however the details and our expectation of a contract award to CBLI have not changed. We have no reason
to believe that BARDA’s intention to award the contract to CBLI has changed.
• There is no fundamental reason for the stock to trade down as it has recently, in our opinion, and while we
anticipate the contract will be awarded shortly, we note that the delay does not jeopardize the company or the
CBLB502 program. Recall CBLI has historically done a lot with a very little amount of cash and currently has a low cash
burn of ~11 million annually.
• Recall that CBLB502, a recombinant protein, protects the two main body systems affected by sub-lethal radiation—
the hematopoietic tissue and gastrointestinal tract. Competitor products in development are potentially complementary
and not a threat, in our opinion, given that their mechanism of action that appears to protect the respiratory track against
radiation. CBLI is also planning a Phase I/II trial in head and neck cancer patients treated with radiation to study its
supportive care.
• Recall, as we had noted previously, we expect that at some point Cleveland BioLabs will also be awarded a contract
to supply the US government with CBLB502 to treat and prevent ARS in the event of a radiological event. Progress
on this front could come in H2:11 with the publication of a Radiation Medical Countermeasure RFP. CBLI has already been
awarded over $48 million in government contracts to develop CBLB502, and we expect that CBLI will submit its BLA in
H1:12. With expected approval by H2:12, we believe that CBLI will be a main supplier of a radiation countermeasure to the
military and Strategic National Stockpile (SNS), given the language in the BAA-BARDA-09-34 solicitation.
• The broad Agency award (BAA-BARDA-09-34) that CBLI anticipates receiving funding from, has the mandate of
funding research and development activities that will serve to advance the knowledge and scientific understanding
of drug candidate countermeasures for chemical, biological, radiological and nuclear (CBRN) threats. This
solicitation includes the anticipation that funding of activities will lead to eventual FDA approval and their inclusion in the
Strategic National Stockpile (SNS).
• Reiterating OUTPERFORM rating and price target of $10/share. We arrive at $10 price target by adding net profits of
CBLB502 from 2011 to 2015, discounted by 30% annually, and applying an 11x multiple to our estimated net profits from
2016 CBLB502 sales also discounted by 30%. Our 11x multiple is arrived at by reducing the present S&P multiple of next
year’s earnings of approximately 13.7x by the expected consensus growth rate for S&P earnings of 23% to account for the
absence of expected growth in the ARS segment of CBLI’s business.
• Risks to the achievement of our fair value estimate include failure to achieve any of the following: completion of CBLB502
development work under the FDA’s Animal Efficacy Rule, FDA approval of CBLB502 for ARS, eventual procurement of
37,500 doses of CBLB502 under the existing DoD/BARDA contract option, and the continued commitment of BARDA and
partner agencies to both developmental funding and procurement of additional defense agents for the SNS.
Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should
be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should
consider this report as only a single factor in making their investment decision. Please see page 3 of this report for analyst
certification and important disclosure information.
2. Milestones
Mid:2011............................Potential $50+ million BARDA development award (BAA-BARDA-09-34)
Mid 2011............................Potential publication of an RFP from BARDA for radiation medical countermeasure
Mid 2011............................Pivotal animal study CBLB502 for BLA
Mid 2011............................Initiation of CBLB502 Safety Study, n=500, double-blind
Q3 2011.............................IND filing for next generation curaxins
2012 ..................................BLA filing for CBLB502
H1:11.................................Initiation of Phase I/II trials of CBLB502 as an adjuvant therapy in head and neck cancer patients
Q4:11.................................Initiation of Phase I trial of CBLB502 in cancer patients
YE:11.................................Completion of CBLC102 PIb liver cancer trial
H2:12.................................Potential FDA approval for CBLB502 as a radiation medical countermeasure
Cleveland BioLabs, Inc.| 2
3. Analyst Certification
I, Gregory R. Wade, Ph.D., David M. Nierengarten, Ph.D., Christopher N. Marai, Ph.D., certify that the views expressed in this report accurately
reflect my personal opinion and that I have not and will not, directly or indirectly, receive compensation or other payments in connection with my
specific recommendations or views contained in this report.
Disclosure information regarding historical ratings and price targets is available at http://www.wedbush.com/ResearchDisclosure/DisclosureQ111.pdf
Investment Rating System:
Outperform: Expect the total return of the stock to outperform relative to the median total return of the analyst’s (or the analyst’s team) coverage
universe over the next 6-12 months.
Neutral: Expect the total return of the stock to perform in-line with the median total return of the analyst’s (or the analyst’s team) coverage
universe over the next 6-12 months.
Underperform: Expect the total return of the stock to underperform relative to the median total return of the analyst’s (or the analyst’s team)
coverage universe over the next 6-12 months.
The Investment Ratings are based on the expected performance of a stock (based on anticipated total return to price target) relative to the
other stocks in the analyst’s coverage universe (or the analyst’s team coverage).*
Rating Distribution Investment Banking Relationships
(as of March 31, 2011) (as of March 31, 2011)
Outperform: 55% Outperform: 11%
Neutral: 37% Neutral: 4%
Underperform: 8% Underperform: 0%
The Distribution of Ratings is required by FINRA rules; however, WS’ stock ratings of Outperform, Neutral, and Underperform most closely
conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS’ stock ratings are on a relative
basis.
The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The
analysts receive compensation that is based upon various factors including WS’ total revenues, a portion of which are generated by WS’
investment banking activities.
Wedbush Equity Research Disclosures as of May 25, 2011
Company Disclosure
Cleveland BioLabs, Inc. 1,7,10
Research Disclosure Legend
1. WS makes a market in the securities of the subject company.
2. WS managed a public offering of securities within the last 12 months.
3. WS co-managed a public offering of securities within the last 12 months.
4. WS has received compensation for investment banking services within the last 12 months.
5. WS provided investment banking services within the last 12 months.
6. WS is acting as financial advisor.
7. WS expects to receive compensation for investment banking services within the next 3 months.
8. WS provided non-investment banking securities-related services within the past 12 months.
9. WS has received compensation for products and services other than investment banking services within the past 12 months.
10. The research analyst, a member of the research analyst’s household, any associate of the research analyst, or any individual
directly involved in the preparation of this report has a long position in the common stocks.
11. WS or one of its affiliates beneficially own 1% or more of the common equity securities.
Price Charts
Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for
companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until
the following quarter. Additional information on recommended securities is available on request.
Cleveland BioLabs, Inc.| 3
4. * WS changed its rating system from (Strong Buy/Buy/Hold/Sell) to (Outperform/ Neutral/Underperform) on July 14, 2009.
Please access the attached hyperlink for WS’ Coverage Universe: http://www.wedbush.com/services/cmg/equities-division/research/equity-
research Applicable disclosure information is also available upon request by contacting Ellen Kang in the Research Department at (213) 688-
4529, by email to ellen.kang@wedbush.com, or the Business Conduct Department at (213) 688-8090. You may also submit a written request
to the following: Business Conduct Department, 1000 Wilshire Blvd., Los Angeles, CA 90017.
OTHER DISCLOSURES
RESEARCH DEPT. * (213) 688-4505 * www.wedbush.com
EQUITY TRADING Los Angeles (213) 688-4470 / (800) 421-0178 * EQUITY SALES Los Angeles (800) 444-8076
CORPORATE HEADQUARTERS (213) 688-8000
The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a
representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be
nor should it be relied upon as a complete record or analysis; neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned
herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and
advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales
thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The
herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the
information contained herein may be obtained upon request.
Cleveland BioLabs, Inc.| 4
5. EQUITY RESEARCH DEPARTMENT
(213) 688-4529
DIRECTOR OF RESEARCH
Mark D. Benson (213) 688-4435
RETAIL AND CONSUMER TECHNOLOGY, MEDIA AND TELECOM LIFE SCIENCES
Consumer Products Communications Equipment Biotechnology/Biopharmaceuticals/BioDefense
Rommel T. Dionisio (212) 938-9934 Rohit Chopra (212) 668-9871 Gregory R. Wade, Ph.D. (415) 274-6863
Kurt M. Frederick, CFA CPA (213) 688-4459 Sanjit Singh (212) 938-9922 David M. Nierengarten, Ph.D. (415) 274-6862
Christopher N. Marai, Ph.D. (415) 274-6861
Entertainment: Toys Entertainment: Retail
Edward Woo, CFA (213) 688-4382 Michael Pachter (213) 688-4474 Cardiac, Hepatic and Regenerative
Nick McKay (213) 688-4343 Duane Nash, MD JD MBA (415) 263-6650
Entertainment: Software Akiva Felt (415) 263-6648
Healthy Lifestyles Michael Pachter (213) 688-4474
Kurt M. Frederick, CFA CPA (213) 688-4459 Edward Woo, CFA (213) 688-4382 Emerging Pharmaceuticals
Nick McKay (213) 688-4343 Liana Moussatos, Ph.D. (415) 263-6626
Specialty Retail: Hardlines Richard Lau (415) 274-6851
Joan L. Storms, CFA (213) 688-4537 Computer Services: Financial Technology Christopher N. Marai, Ph.D. (415) 274-6861
John Garrett (213) 688-4523 Gil B. Luria (213) 688-4501
Nick Setyan (213) 688-4519 Healthcare Services - Managed Care
Specialty Retail: Softlines Sarah James (213) 688-4503
Betty Chen (415) 273-7328 Internet and E-Commerce Daniel Patt (212) 938-9937
Kerry Rice, CPA (213) 688-4538
RETAIL/CONSUMER MARKET RESEARCH John Kim (213) 688-6624 Medical Technology
Phillip Nalbone (415) 274-6884
Gabriella Santaniello (213) 688-4557 Edward Woo, CFA (213) 688-4382 Jeffrey Chu (415) 274-6885
Nick McKay (213) 688-4343
CLEAN TECHNOLOGY AND INDUSTRIAL GROWTH Medical Diagnostics and Life Sciences Tools
Media Zarak Khurshid (415) 274-6823
Aerospace and Defense James Dix, CFA (213) 688-4315
Kenneth Herbert (415) 274-6875 Max Pinigin (213) 688-4518
Andrew Doupé (415) 274-6876
Movies and Entertainment
Clean Technology Michael Pachter (213) 688-4474
Craig Irwin (212) 938-9926 Edward Woo, CFA (213) 688-4382
David Giesecke (212) 938-9925 Nick McKay (213) 688-4343
Environmental Services Semiconductors
Al Kaschalk (213) 688-4539 Betsy Van Hees (415) 274-6869
Kevin Lee (213) 688-4303 Ryan Jue (415) 263-6669
Industrial Biotechnology Telecommunications Software
Liana Moussatos, Ph.D. (415) 263-6626 Scott P. Sutherland, CFA (213) 688-4522
Christopher N. Marai, Ph.D. (415) 274-6861 Suhail Chandy (213) 688-4380
Water and Renewable Energy Solutions Wireless Equipment
David Rose, CFA (213) 688-4319 Scott P. Sutherland, CFA (213) 688-4522
Suhail Chandy (213) 688-4380
EQUITY SALES EQUITY TRADING
Los Angeles (213) 688-4470 / (800) 444-8076 Los Angeles (213) 688-4470 / (800) 421-0178
San Francisco (415) 274-6800 San Francisco (415) 274-6811
New York (212) 938-9931 New York (212) 344-2382
Boston (617) 832-3700 Boston (617) 832-3700
CORPORATE HEADQUARTERS
1000 Wilshire Blvd., Los Angeles, CA 90017-2465
Tel: (213) 688-8000 www.wedbush.com